| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZCCHC6 |
| Uniprot No | Q5VYS8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-412 aa |
| 活性数据 | MGDTAKPYFVKRTKDRGTMDDDDFRRGHPQQDYLIIDDHAKGHGSKMEKGLQKKKITPGNYGNTPRKGPCAVSSNPYAFKNPIYSQPAWMNDSHKDQSKRWLSDEHTGNSDNWREFKPGPRIPVINRQRKDSFQENEDGYRWQDTRGCRTVRRLFHKDLTSLETTSEMEAGSPENKKQRSRPRKPRKTRNEENEQDGDLEGPVIDESVLSTKELLGLQQAEERLKRDCIDRLKRRPRNYPTAKYTCRLCDVLIESIAFAHKHIKEKRHKKNIKEKQEEELLTTLPPPTPSQINAVGIAIDKVVQEFGLHNENLEQRLEIKRIMENVFQHKLPDCSLRLYGSSCSRLGFKNSDVNIDIQFPAIMSQPDVLLLVQECLKNSDSFIDVDADFHARVPVVVCREKQRSHFFKLFIY |
| 分子量 | 74.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ZCCHC6蛋白的3篇代表性文献(注：文献为示例性内容，具体信息需结合真实数据库验证)：
---
1. **文献名称**: *ZCCHC6 mediates RNA methylation to promote cancer progression*
**作者**: Li Y. et al.
**摘要**: 本研究揭示了ZCCHC6通过催化mRNA中N6-甲基腺苷(m6A)修饰，调控致癌基因的稳定性及翻译效率，促进肿瘤生长。作者利用重组ZCCHC6蛋白验证其甲基转移酶活性，并证明其与肝癌患者预后相关。
2. **文献名称**: *Structural and functional analysis of ZCCHC6 in antiviral immunity*
**作者**: Wang X. et al.
**摘要**: 本文解析了重组人ZCCHC6蛋白的晶体结构，发现其通过锌指结构域结合病毒RNA，抑制病毒复制。实验表明，ZCCHC6缺失导致细胞对RNA病毒感染的敏感性增加。
3. **文献名称**: *ZCCHC6 modulates pluripotency via TERRA RNA regulation*
**作者**: Zhang R. et al.
**摘要**: 研究显示，ZCCHC6通过重组蛋白体外实验结合端粒相关RNA(TERRA)，影响端粒长度和胚胎干细胞的自我更新能力，为干细胞多能性调控提供新机制。
---
**注意**：以上文献信息为模拟示例，实际研究需通过PubMed、Web of Science或Google Scholar等平台检索关键词“ZCCHC6”、“recombinant ZCCHC6”获取真实数据。近期研究多集中于RNA修饰、癌症及干细胞领域。
ZCCHC6 (Zinc Finger CCHC-Type Containing 6) is a human protein belonging to the zinc finger protein family, characterized by its conserved CCHC-type zinc finger motif. It is a non-canonical RNA methyltransferase implicated in post-transcriptional RNA modifications, particularly N6-methyladenosine (m6A), a pivotal epigenetic regulator influencing RNA stability, splicing, and translation. Structurally, ZCCHC6 contains a catalytic methyltransferase domain and a C-terminal RNA-binding domain, enabling its interaction with RNA molecules and co-factors.
Emerging studies highlight its role in RNA metabolism and antiviral immunity. ZCCHC6 facilitates m6A methylation of specific viral RNAs (e.g., HIV-1) or cellular RNAs, modulating viral replication or host immune responses. It interacts with innate immune signaling pathways, including RIG-I/MDA5. to suppress antiviral signaling, suggesting a dual regulatory mechanism in infection and immunity. Additionally, ZCCHC6 is linked to cancer progression. Overexpression in malignancies like hepatocellular carcinoma and breast cancer correlates with enhanced cell proliferation, metastasis, and chemotherapy resistance, potentially through m6A-dependent regulation of oncogenic transcripts.
Despite these insights, ZCCHC6's substrate specificity, molecular partners, and disease-related mechanisms remain incompletely defined. Its therapeutic potential as a target in cancer or viral infections is an active area of investigation.
×
